Drug intelligence / Profile preview

HD6-NOTA

Development stage: Preclinical
Lead developer: Ashvattha Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

HD6-NOTA is a preclinical radiotracer developed by Ashvattha Therapeutics for imaging tumor-associated macrophages in cancer. It consists of a sixth-generation hydroxyl dendrimer (HD6) conjugated to NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), a bifunctional chelating agent that enables radiolabeling for PET imaging. The dendrimer platform provides enhanced tumor targeting while NOTA serves as the chelator for radioisotope attachment, creating a superior imaging agent for visualizing and quantifying TAMs in the tumor microenvironment.

Other names: hydroxyl dendrimers Generation 6-NOTA

Targets

TAM (TAM receptor tyrosine kinases)

Beyond the preview

Go deeper on HD6-NOTA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD6-NOTA.

Explore the full profile